SAVOR-TIMI 53 study: saxagliptin had better glucose control than placebo but no cardiovascular benefit

AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in type II diabetes but has failed to show a benefit in terms of cardiovascular outcomes. At the European Society of Cardiology Annual Congress Dr Deepak Bhatt MD, Professor of Medicine at Harvard Medical School and Chief of Cardiology, VA Boston Healthcare System Brigham and Women’s Hospital explains that this agent should be a useful addition in second and third line treatment.